EPI-506

EPI-506 (developed by Essa Pharma) is an experimental compound in phase I/II development for prostate cancer.[1] It is the successor of EPI-001 and targets the N-terminal domain of the androgen receptor. This mechanism of action is believed to allow the drug to block signaling from the androgen receptor and its splice variants.[2][3]

References



This article is issued from Wikipedia - version of the Tuesday, May 03, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.